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The mechanism of glycosphingolipid degradation
revealed by a GALC-SapA complex structure
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Sphingolipids are essential components of cellular membranes and defects in their synthesis
or degradation cause severe human diseases. The efﬁcient degradation of sphingolipids in the
lysosome requires lipid-binding saposin proteins and hydrolytic enzymes. The glyco-
sphingolipid galactocerebroside is the primary lipid component of the myelin sheath and is
degraded by the hydrolase β-galactocerebrosidase (GALC). This enzyme requires the saposin
SapA for lipid processing and defects in either of these proteins causes a severe neurode-
generative disorder, Krabbe disease. Here we present the structure of a glycosphingolipid-
processing complex, revealing how SapA and GALC form a heterotetramer with an open
channel connecting the enzyme active site to the SapA hydrophobic cavity. This structure
deﬁnes how a soluble hydrolase can cleave the polar glycosyl headgroups of these essential
lipids from their hydrophobic ceramide tails. Furthermore, the molecular details of this
interaction provide an illustration for how speciﬁcity of saposin binding to hydrolases is
encoded.
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Sphingolipids are both essential membrane components andbioactive metabolites that regulate critical cell functions.Defects in sphingolipid metabolism underlie a range of
diseases, including lysosomal storage diseases, and are implicated
in a number of cancers1–3. Sphingolipid degradation occurs in the
lysosome and depends upon two families of proteins: glycosyl
hydrolases, and lipid-transfer proteins including saposins and the
GM2 activator protein4–7. The hydrolases are water soluble while
the substrates are embedded in lysosomal intraluminal vesicle
membranes. The steric crowding of headgroups and lateral
association of sphingolipids into clusters prevents hydrolases
from accessing the scissile bonds of their target substrates.
Saposins are required to facilitate sphingolipid processing by
hydrolases, and extensive work provides evidence for two general
models of saposin action8–11 (Fig. 1a). The ‘solubiliser’ model
proposes the complete extraction of lipids from the membrane,
while the ‘liftase’ model envisages saposin proteins binding
directly to compatible membranes and improving lipid accessi-
bility by membrane distortion, destabilisation or localised remo-
delling. The saposin proteins are produced as a precursor
prosaposin protein that, upon delivery to the lysosome, is cleaved
into the four saposins: A, B, C and D12–14. The functions of these
four saposins are distinct, as they cannot compensate for the loss
of each other, and saposins appear to function speciﬁcally with
their associated hydrolase15,16. Lysosomal storage diseases, and
more speciﬁcally sphingolipidoses, are caused by mutations that
inhibit degradation of sphingolipids. For example, Krabbe disease
is caused by loss of galactocerebrosidase (GALC) which is
responsible for the removal of the terminal galactose from the
glycosphingolipid galactocerebroside (GalCer, Fig. 1b). Impor-
tantly, mutation of the GALC-associated saposin SapA can also
cause Krabbe disease17,18. Similarly, Gaucher disease is caused by
loss of glucocerebrosidase activity and also by loss of SapC,
highlighting the critical role of saposins in sphingolipid proces-
sing19–21.
Several high-resolution structures of saposins have been
determined to date, revealing huge conformational variability and
a propensity to form oligomeric assemblies22–26. Saposins can
broadly be described as existing in two states: a “closed” mono-
meric form where the helical protein folds back on itself, burying
a large hydrophobic core; or a more “open” dimeric form, pos-
sessing a hydrophobic cavity into which lipids and detergents can
bind. A recent structure of SapA, solved in the presence of the
detergent LDAO, revealed that this open conformation can form
lipoprotein discs22 and these discs (also referred to as picodiscs or
Salipro nanoparticles) have recently been exploited to aid the
determination of challenging membrane protein structures by
crystallography and cryo-electron microscopy27. However, it has
remained unclear what form of saposin–lipid complex mediates
binding to their cognate hydrolase. To remedy this deﬁcit we have
solved the structure of GALC in complex with SapA, deﬁning
how saposins solubilise lipids for processing by soluble
hydrolases.
Results
GALC and SapA form a pH-dependent heterotetrameric
complex. Murine GALC and SapA were expressed and puriﬁed
from mammalian cells and E. coli, respectively. Pulldown assays
reveal that SapA binding to GALC is pH-dependent and is
optimal at low pH, equivalent to that of the endolysosomal
compartments where lipid degradation occurs (Fig. 2a). This
interaction depends upon the presence of detergents, suggesting
that the “open” (dimeric) lipid-bound form of SapA mediates the
interaction (Fig. 2b). The pH-dependency of the interaction,
combined with the low pI of SapA (pH 4.5) and the higher pI of
GALC (pH 6.1), suggests that the interaction could be mediated
by electrostatic interactions. In support of this, the interaction is
sensitive to the presence of salt, as increasing concentrations of
NaCl reduce binding in these pulldown assays (Fig. 2b). Based on
these insights, the GALC–SapA complex was formed at pH 5.0 in
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Fig. 1 Glycosphingolipid processing by saposins and GALC. a Schematic diagram for the two proposed mechanisms of saposin-mediated hydrolase
activation. The solubiliser model (left) proposes saposins (yellow) extract sphingolipids from the bilayer, forming a soluble saposin-lipid complex that
presents the lipid to the hydrolase (blue). The liftase model (right) proposes saposins (orange) disrupt or insert into the bilayer to provide access for
hydrolases (purple) to the lipid substrates at the bilayer surface. Glycosyl headgroups are illustrated as green hexagons. b The cleavage of
galactocerebroside (GalCer) by GALC produces galactose and ceramide
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the presence of the detergent LDAO and the X-ray crystal
structure of this complex solved and reﬁned to 3.6 Å resolution
(Fig. 2c and Table 1). The structure was solved by molecular
replacement using the high-resolution structure of GALC (dmin =
1.97 Å, PDB 4CCE28) as a search model. After placement of two
GALC molecules, strong FO–FC density was evident and could be
readily interpreted as two molecules of SapA (Supplementary
Fig. 1a).
The structure reveals that the complex forms a 2:2 hetero-
tetramer, composed of a central SapA dimer with two molecules
of GALC binding its surface. The SapA–GALC heterodimers are
related to each other by a pseudo two-fold non-crystallographic
symmetry axis. Using a high-resolution GALC structure, and thus
high-quality phase information, to solve the complex structure
yielded excellent maps: the SapA molecules could be unambigu-
ously positioned due to density for their intramolecular
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Fig. 2 GALC–SapA complex formation and structure. a Coomassie-stained SDS–PAGE of pulldown assays with immobilised GALC across the pH range 7.5
to pH 4.5 in the presence of detergent. The intensity of SapA binding to GALC is 3.6 times greater at pH 5.5, equivalent to the late-endosomal/lysosomal
compartment (n= 3). Glycosylation of GALC results in a smeared band on gradient SDS-PAGE gels. b Pulldown assays at pH 5.4 identify that the
interaction requires the presence of detergents, such as Tween 20 or LDAO, and is reduced with increasing NaCl concentration (20, 150 and 300mM
NaCl). c The crystal structure of the GALC–SapA complex reveals a pseudo-symmetric 2:2 heterotetramer of SapA (yellow and orange) with GALC (cyan
and magenta). d The interacting surfaces of GALC (left) and the SapA dimer (right), rotated by 90° with respect to c to highlight the respective interaction
surfaces. On the GALC surface the interacting regions contacted by SapA chain 1 (yellow) and SapA chain 2 (orange) are highlighted, the different domains
of GALC are outlined (white lines) and the active site is identiﬁed. On the SapA surface the residues that interact with GALC are highlighted for each chain
and the different chains of SapA are outlined (white line)
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disulphide bonds, and small GALC conformational changes in
the vicinity of the bound SapA molecules were readily visible
(Supplementary Fig. 1b–d). By peeling apart the complex
structure the details of the surfaces involved in the interaction
between GALC and SapA are revealed (Fig. 2d). Importantly, the
active site of GALC is buried in the centre of the interaction
interface. Not only does the SapA dimer sit over the active site, it
makes contact with all three domains of GALC: the TIM barrel,
β-sandwich and lectin domains29. This extensive interface buries
a total surface area of 1366 Å2, of which 70% is contributed by
one SapA chain and 30% by the other (yellow and orange,
respectively, in Fig. 2d). At the optimal pH of the interaction the
GALC and SapA surfaces demonstrate extensive charge com-
plementarity, explaining the observed pH dependency of the
interaction (Supplementary Fig. 2). The GALC–SapA interaction
interface is not in the vicinity of any crystal contacts and thus is
not affected by surrounding molecules in the crystal (Supple-
mentary Fig. 1e).
The GALC–SapA complex possesses a hydrophobic channel.
Analysis of the SapA dimer in the complex structure suggests the
presence of disordered detergent within the core. Hydrophobic
residues line the SapA core, consistent with this surface being
exposed to non-polar solvent (Fig. 3a, the right panel reveals the
internal surface of the dimer). Further, the average electron
density in the cavity is lower than the surrounding solvent,
consistent with the presence of detergent (Supplementary Fig. 3a).
Analysis of the SapA dimer surface reveals a clear hydrophobic
patch, within the interaction interface, at the point where the two
SapA chains come together to contact the GALC surface (Fig. 3a,
circled in the central panel, and Fig. 2d). A cross-section through
the structure at this position shows that this hydrophobic patch
encircles an opening in the SapA dimer surface that lies directly
opposite the GALC active site (Fig. 3b). This reveals a continuous
open channel that stretches from the GALC active site through to
the hydrophobic cavity buried in the SapA dimer. The hydro-
phobic acyl chains of glycosphingolipids such as GalCer can thus
be shielded from the polar solvent by the SapA dimer, while the
hydrophilic glycosyl head groups are presented to the GALC
active site. Although GALC–SapA crystals could be obtained in
the presence of lipids and substrate-mimics, we were not able to
collect data of sufﬁcient quality to yield a structure of the
substrate–bound complex. However, our previous work
Table 1 Data collection and reﬁnement statistics
Data collection
Space group P 62 2 2
Cell dimensions
a,b,c (Å) 187.2, 187.2, 360.2
Resolution (Å) 180.12–3.60 (3.70–3.60)
Rmerge 0.386 (2.946)
Rpim 0.078 (0.607)
CC1/2 0.945 (0.677)
I/σI 9.3 (1.5)
Wilson B (Å2)a 94.5
Completeness (%) 100 (100)
Redundancy 25.6 (25.2)
Reﬁnement
Resolution (Å) 162.11–3.60
No. reﬂections in working set 43,825
No. reﬂections in test set 2138
Rwork/Rfree 0.217/0.231
No. atoms
Protein 11,522
Otherb 220
B-factors (Å2)
Protein 100.9
Otherb 141.2
Ramachandran
Favoured (%) 95.8
Outliers (%) 0.5
r.m.s. deviations
Bond lengths (Å) 0.008
Bond angles (°) 0.94
Values in parentheses are for highest-resolution shell
aCalculated using phenix.model_vs_data59
bIncludes carbohydrate and ions
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Fig. 3 The GALC–SapA structure reveals a hydrophobic channel buried in
the core of the complex. a Residue hydrophobicity (green) is mapped onto
the surface of the SapA dimer. The left panel is in the same orientation as
shown in Fig. 2c, while the central panel is rotated by 90° to be in the same
orientation as Fig. 2d. The region that binds over the GALC active site is
circled (red dashed line). The right panel maintains the orientation of the
central panel, with one SapA chain removed to reveal the highly
hydrophobic inner surface of the SapA dimer. b Cross-section through the
GALC–SapA structure reveals an open channel stretching from the GALC
active site into the SapA hydrophobic cavity. The GALC surface and cut-
through is shown in cyan and the SapA dimer surface is shown in yellow
and orange. For clarity, the second GALC monomer is not shown. An
expanded view of the active site (bottom left panel) illustrates how
substrate binds in this pocket based on the previously determined
substrate–bound GALC structure (PDB ID 4CCC,28) and identiﬁes the
scissile bond (white bolts). c Illustration of the hydrophobic cavity (green)
showing that the lipidated substrate GalCer (pink sticks) can ﬁt into this
cavity, bridging the channel from the GALC active site to hydrophobic SapA
core. d Residues that form the opening at the SapA dimer surface opposite
the GALC active site are shown as sticks with a semi-transparent surface.
The displayed region of the SapA dimer is the same as that circled in
panel a
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identifying how a bona ﬁde synthetic substrate binds the GALC
active site (Fig. 3b inset) was used to guide the placement of a
lipidated substrate in this channel28. The position of the galactose
headgroup of GalCer and the orientation of the scissile bond can
therefore be reliably deﬁned and is compatible with the acyl
chains being oriented into the hydrophobic channel. Previous
work has shown that, upon binding of substrate, GALC residues
E182 and R380 undergo conformational changes to allow posi-
tioning of the remainder of the substrate leaving group28.
Although this plasticity near the active site and the conforma-
tional ﬂexibility of the GalCer acyl chains hindered accurate
modelling of the conformation of an entire GalCer molecule, the
dimensions of the channel and hydrophobic cavity could
accommodate the lipidated substrate (Fig. 3c). Based on the SapA
lipoprotein disc structure containing ordered LDAO molecules,
the volume of the SapA dimer cavity in our structure is sufﬁcient
to contain between 10 and 14 molecules of LDAO (Supplemen-
tary Fig. 3b) and therefore would be capable of binding at least 2
molecules of GalCer, meaning both GALC molecules in the
complex could function simultaneously. The opening in the SapA
dimer surface through which the GalCer acyl chains must pass is
surrounded by both hydrophobic and polar residues from both
SapA chains (Y30, T34, W37 and I38 from one SapA, and Y54,
V57, I58 and M61 from the second SapA, Fig. 3d). The orien-
tation of W37 and I38 differs from that of the lipoprotein disc
structure and is inﬂuenced by interactions with the GALC sur-
face. As was observed for substrate-bound GALC, it is likely that
additional residues in this region may alter their conformation in
order to accommodate lipidated substrate. In particular, residue
Y54, which is highly conserved across the saposin family, forms
the limiting edge of the channel nearest the active site and thus
may play a critical role in substrate positioning. The presence of
this continuous channel from the active site to the hydrophobic
cavity, with sufﬁcient space to accommodate glycosylated
sphingolipid substrates, supports that this arrangement of GALC
and SapA represents the functional complex that facilitates gly-
cosphingolipid catabolism in vivo.
Speciﬁc mutations of SapA inhibit binding to GALC. Analysis
of the molecular details at the interface reveals that several
sidechains of residues along the length of one SapA chain form
critical hydrogen bonds, electrostatic and hydrophobic interac-
tions with residues in GALC (Fig. 4a and Supplementary Fig. 4).
These interactions span two stretches of this SapA chain: residues
19–32 and 49–63. The interactions contributed by the second
SapA chain encompass residues 36–40 and involve several
backbone hydrogen bonds, as well as sidechain interactions with
W37. To conﬁrm that the interface observed in our crystal
structure mediates the interaction in solution, a series of point
mutations were made in SapA and tested for their ability to bind
GALC (Fig. 4b, c). Several of the SapA residues that lie at the
interface with GALC are acidic: E25, E32, E49, D52 or D60.
Single-charge inversions at these sites each abolish or signiﬁcantly
reduce binding to GALC, highlighting the electrostatic nature of
the interface. To ensure that alteration of surface charge alone is
not sufﬁcient to abolish binding we mutated residue E65, which
does not lie in the interface, to lysine and conﬁrmed it does not
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Fig. 4 Critical residues at the GALC–SapA interface. a Schematic diagram illustrating the backbone (bb) hydrogen bonds, sidechain (sc) hydrogen bonds
and salt bridges observed between GALC (cyan) and speciﬁc residues of SapA chains 1 (yellow) or 2 (orange). Note that SapA residues Q24 and W37
interact with multiple GALC residues. b Coomassie-stained SDS–PAGE of pulldown assays with immobilised GALC performed in the presence of Tween-20
identiﬁes critical SapA mutations at the interface that abolish GALC binding in solution. c Quantiﬁcation of SapA binding in pulldown assays (n= 3, error
bars represent SEM)
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interfere with SapA binding to GALC. In addition to electrostatic
interactions, hydrophobic interactions at the interface are also
critical for binding. The sidechain of L28 interacts with a
hydrophobic surface of GALC (Supplementary Fig. 4c) and
mutation of this residue to either arginine or asparagine sig-
niﬁcantly reduces SapA binding to GALC. Residue N21 lies at the
interaction interface and forms a backbone hydrogen bond with
G144 (Supplementary Fig. 4c). In the context of the cell this
highly conserved residue is post-translationally glycosylated and
the position of this sidechain at the surface of GALC is compa-
tible with this modiﬁcation. In an attempt to mimic this bulky
modiﬁcation, which is capable of both hydrophobic and
hydrogen-bond interactions, N21 was mutated to tyrosine. This
mutation did not interfere with SapA binding to GALC, con-
sistent with the binding of glycosylated SapA to GALC in vivo.
Residue 24 is a glutamine that forms hydrogen bonds with resi-
dues T523 and R520 of GALC (Fig. 4a and Supplementary
Fig. 4c). In human SapA the corresponding residue is a glutamate,
which could form a salt bridge with R520. Mutation of Q24 to
lysine blocks SapA binding to GALC, supporting its role in sta-
bilisation of the interaction. The backbone of residue K19 forms a
hydrogen bond with GALC residue S146, while the acyl region of
the K19 sidechain forms hydrophobic interactions with the
GALC surface. It is likely that the disruption of this hydrophobic
interaction, rather than the charge inversion by substitution of
K19 for glutamate, abolishes the GALC–SapA interaction. The
only sidechain from the second SapA molecule that interacts with
the GALC surface is W37. This large sidechain contributes both
hydrophobic and hydrogen bond interactions at the interface and
several mutations of this residue were tested for their ability to
bind GALC. All three mutations W37S, W37D and W37F
maintained close to wild-type levels of binding suggesting that, in
the context of this pulldown, the contribution of W37 is less
critical than that of other interface residues (Fig. 4). However,
W37 forms part of the opening through which the acyl chains of
the substrate must pass (Fig. 3d). This suggests that, although it
may not be essential for the interaction with GALC, W37 is likely
to play a critical role in substrate positioning. Taken together, our
mutational analysis highlights the crucial importance of SapA
residues K19, Q24, E25, L28, E32, E49, D52 and D60 for complex
formation.
GALC binds speciﬁcally to SapA. There is high structural
similarity between the different saposin proteins30, suggesting
that the speciﬁc binding to their cognate enzyme is sequence-
mediated. The identiﬁcation here of speciﬁc residues essential for
SapA binding to GALC provides a framework for understanding
this speciﬁcity. Sequence alignments of saposins A-D reveal the
limited conservation between saposins and identiﬁes several
charge inversions equivalent to those used in this study, parti-
cularly in the region spanning residues 19–32 (Fig. 5a and b).
Based on our binding data, single point mutations in SapA are
sufﬁcient to inhibit binding to GALC and thus the limited con-
servation with saposins B, C and D suggests they would be unable
to bind GALC. While we were unable to purify murine SapC, we
observed that murine GALC (mGALC) binds speciﬁcally to SapA
but not to murine SapB (mSapB) or mSapD (Fig. 5c). We were
able to purify small quantities of human GALC (hGALC) and
human SapC (hSapC), allowing us to test their binding in pull-
down assays. While we could detect GALC binding to SapA, there
was no detectable direct binding to SapC (Supplementary Fig. 5).
Thus, despite the high structural homology of the saposin pro-
teins it is their distinct sequences across the three regions iden-
tiﬁed here as involved in binding to GALC that determine the
binding speciﬁcity for their cognate hydrolases.
Discussion
Here we reveal molecular details of how glycosphingolipids can
be bound by SapA and presented to the active site of GALC for
catabolic processing. The interaction of SapA with GALC is pH
dependent and optimal at pH 5–6, consistent with its activity in
the late endosomal/lysosomal compartments. This pH depen-
dence can be understood by enhanced charge complementarity
between GALC and SapA at pH 5.4 (Supplementary Fig. 2). The
GALC–SapA interaction also requires the presence of detergents,
a proxy for the biological lipid substrates. Structures of SapA in
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Fig. 5 Saposin speciﬁcity. a Sequence alignment of human and murine saposins A–D coloured by conservation. Important residues at the GALC–SapA
interface are highlighted (*). Coloured bars below the sequence identify the regions that interact with GALC: two regions from SapA chain 1 (yellow) and
the one from SapA chain 2 (orange) as detailed in Fig. 4a. The position of α-helices in SapA are highlighted (green cylinders). b Critical residues that may
determine binding speciﬁcity are shown (sticks) on SapA (yellow) at the interface with GALC (cyan surface, key residues depicted as transparent sticks).
Hydrogen bonds between GALC and SapA residues are highlighted (orange dotted lines). c Coomassie-stained SDS-PAGE pulldowns with immobilised
murine GALC (mGALC) illustrating speciﬁc binding of murine SapA (mSapA), but not mSapB or mSapD
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the absence of detergents remain closed24,31 whereas in the pre-
sence of detergents SapA adopts an open conformation (this
study and Popovic et al.22), suggesting that detergent mediates the
formation of open SapA dimers essential for the interaction. The
crystal structure of GALC–SapA determined here reveals the
complex to be a heterotetramer with an extensive interaction
interface that involves residues from all domains of GALC and
both chains of the SapA dimer. There is an open channel running
from the GALC active site through to the hydrophobic cavity of
the SapA dimer, suggesting a clear mechanism for glyco-
sphingolipid binding and processing. The combination of struc-
ture analysis, pulldown assays and sequence comparison of the
saposin family members identiﬁes residues 19, 24, 25, 28, 32, 49,
52 and 60 of SapA as essential for binding to GALC. Despite the
structural homology of the saposin proteins it is clear that the
distinct charge and shape complementarity of the SapA surface is
critical for speciﬁc binding to GALC.
The speciﬁc importance of SapA for mediating GALC activity
in vivo is highlighted by two key observations: clinical data has
identiﬁed that a mutation in SapA causes Krabbe disease despite
normal GALC activity17, and a transgenic mouse with defective
SapA develops a phenotype resembling late-onset Krabbe dis-
ease18. In support of this speciﬁcity, mutations that result in
defective SapC cause Gaucher disease, not Krabbe disease19–21.
However, in vitro studies of saposin-mediated degradation of
galactosphingolipids have shown that both SapA and SapC can
stimulate GALC activity32,33. Our pulldown studies using
recombinant GALC and saposins (Fig. 5c and Supplementary
Fig. 5) suggest that, unlike SapA, SapC does not directly bind
GALC. Taken together, this suggests that although SapC is not
necessary for GALC activity in vivo it may indirectly enhance
GALC activity by, for example, aiding lipid accessibility at the
bilayer surface.
The GALC–SapA complex structure reveals new details of how
saposins bind to lysosomal hydrolases. However, it is not the ﬁrst
SapA dimer structure and comparison with the previous structure
of a human SapA lipoprotein disc reveals signiﬁcant differences in
dimer assembly22. Interestingly, the conformation of the SapA
monomers in these structures are essentially identical (RMSD
0.86 Å2 over 80 Cα atoms, with 79.7% sequence identity),
adopting the same hinge angle upon dimer formation (Supple-
mentary Fig. 6a). Despite this similarity, the relative orientations
of the monomers within the dimer differs between these struc-
tures (Supplementary Fig. 6b). In our structure the monomers are
head-to-head, with all termini together at one end, while in the
published lipoprotein disc structure the monomers adopt a head-
to-tail orientation. However, molecular dynamics studies of the
previous lipoprotein disc structure and subsequent work mon-
itoring the dynamics of these particles shows there is signiﬁcant
plasticity in the arrangement of the SapA molecules as their
relative orientations are only determined via binding to LDAO
(Supplementary Fig. 6c)22,34,]. In complex with GALC, the SapA
dimer possesses direct protein-protein contacts between saposin
monomers, including extensive hydrophobic interactions where
the termini come together and additional contacts near the
interface with GALC (Supplementary Fig. 6d). Comparison of the
different SapA dimer structures shows that the GALC-interacting
surface identiﬁed in our structure is surface exposed in the
lipoprotein disc structure. Docking of GALC onto the surface of
the lipoprotein disc structure reveals this SapA dimer to be
compatible with GALC binding (Supplementary Fig. 7a). In this
alternative arrangement the opening on the surface of the SapA
dimer is less hydrophobic and, due to the loss of interactions with
the second SapA chain, the substrate channel is more open and
exposed to surrounding solvent (Supplementary Fig. 7b, c).
Although there are no steric clashes that would prevent this
complex forming, the tighter SapA dimer and enclosed hydro-
phobic channel identiﬁed in our complex provides a more pro-
tected environment from the hydrophilic solvent. We therefore
propose that our structure, possessing a large buried surface area,
an enclosed hydrophobic channel and an obvious mechanism for
substrate presentation to GALC, represents the bona ﬁde inter-
action that stimulates SapA-mediated lipid catabolism in the
lysosome.
As both open and closed forms of SapA have been described
we considered whether the closed, monomeric conformation
could be compatible with binding to GALC. Closed SapA can be
docked onto the open form of SapA via either the terminal
helices or the central two helices (Supplementary Fig. 8a). Only
this second alignment yields an interface that maintains any of
the critical interactions identiﬁed in our pulldowns (Supple-
mentary Fig. 8b). This arrangement would block binding of a
second SapA and GALC, resulting in a 1:1 complex possessing a
buried surface area of 669 Å2 (compared with 1366 Å2 for the
tetramer) that is not predicted by ePISA to form a stable com-
plex (CSS = 0)35. Thus, although there is no steric hindrance to
binding of closed SapA to GALC it is likely to be an extremely
weak interaction, below the detection limit of our assays, if it
exists at all.
Previous work has identiﬁed the pathogenic mechanisms
underlying speciﬁc disease-causing mutations of GALC, including
protein misfolding and active site defects28,36. Two mutations
responsible for causing Krabbe disease, E215K and P302R, have
been shown to trafﬁc correctly in cells, identifying that they are
correctly folded, and retain enzymatic activity36–39. These two
mutations lie on the GALC surface adjacent to the SapA inter-
action site (Supplementary Fig. 9). Although these residues do not
form direct interactions with SapA residues, their proximity to
the binding site and their mutation to bulky, charged sidechains
suggests these mutations may alter the surface shape and surface
charge of GALC, interfering with binding to SapA. Thus, an
inability to bind their cognate saposin may represent a new
pathologic mechanism for sphingolipidoses.
Our structure reveals how saposins and hydrolytic enzymes
can interact and can be compared with the recent structures of
acid sphingomyelinase (ASM), which possesses an intra-
molecular saposin-like domain40–42. Although the enzymatic
portion of ASM is not structurally similar to GALC, the saposin-
like region adopts a similar conformation to SapA in the
GALC–SapA complex, allowing a reliable overlay to be made
based on this portion (Supplementary Fig. 10a). This compar-
ison reveals that the catalytic domains are in similar positions
relative to the saposin (or saposin-like domain) and that the
enzyme active sites are adjacent to the saposin, although not
directly overlaid (Supplementary Fig. 10b). However, there are
signiﬁcant differences between these structures and this may
reﬂect the different mechanisms by which the saposin domains
facilitate lipid processing. Speciﬁcally, SapA is thought to
function as a ‘solubiliser’, an assertion strongly supported by
both the GALC–SapA structure presented here and the SapA
lipoprotein disc structure22. ASM, on the other hand, is likely to
function via a ‘liftase’ mechanism. Speciﬁcally, ASM has been
shown to bind tightly to negatively charged membranes and the
saposin domain is likely to play a critical role in orienting the
active site towards the membrane41,43. Dimerisation of the
saposin-like domain would not be required in this ‘liftase’ model
of ASM activity, and indeed we observe that steric hindrance
would prevent formation of a SapA-like dimer by the ASM
saposin-like domain. We therefore conclude that the mechan-
isms used by saposins to facilitate lipid presentation will inﬂu-
ence the stoichiometry and topology of their association with
their cognate hydrolases.
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Methods
Protein expression and puriﬁcation. His6-tagged murine GALC (mGALC) was
expressed using our stably transfected HEK 293 T cell line and puriﬁed from
conditioned medium using nickel-afﬁnity chromatography (Ni-NTA agarose resin)
in phosphate-buffered saline pH 7.428,31. Untagged murine SapA (mSapA) was
expressed in Escherichia coli Origami (DE3) cells and puriﬁed as follows. Cleared
lysate was heat-treated (100 °C, 30 min), precipitated proteins were cleared by
centrifugation (40,000 g, 40 min) and supernatant containing mSapA was dialysed
overnight in the presence of 20 µg mL−1 DNAse against anion exchange buffer (50
mM Tris pH 7.4, 25 mM NaCl). mSapA was further puriﬁed by anion exchange
chromatography (HiTrap QSepharose column) followed by size-exclusion chro-
matography (HiLoad 16/600 Superdex 75 column) in 50 mM Tris pH 7.4, 150 mM
NaCl28,31. mSapA mutants were made by site-directed mutagenesis and veriﬁed by
sequencing (Supplementary Table 1). Mutant proteins were expressed and puriﬁed
exactly as for wild-type. Puriﬁed mGALC was concentrated to 5–15 mgml−1 and
stored in phosphate-buffered saline pH 7.4 at 4 °C. Puriﬁed mSapA was con-
centrated to 8.0 mg ml−1 and stored in 50 mM Tris pH 7.4, 150 mM NaCl at 4 °C.
mSapB, mSapD and hSapC cDNA was synthesised (GeneArt) and cloned into the
pET15b vector using NcoI and XhoI restriction-endonuclease sites. Untagged
mSapB, mSapD and hSapC were expressed and puriﬁed as for mSapA31. Human
GALC (hGALC) was expressed and puriﬁed as described above with minor
modiﬁcations as follows28,29. The cDNA encoding hGALC was obtained from the
IMAGE clone library and cloned into pSecTag2B with an N-terminal His tag and
Factor Xa site and conﬁrmed by sequencing. This construct was transfected into
HEK 293 T cells and a cell line generated by clonal selection that stably expressed
hGALC. Protein was puriﬁed by nickel-afﬁnity chromatography, as described
above for mGALC29.
Pulldowns. mGALC was mixed with magnetic Ni-NTA agarose beads under
saturating conditions (30 μl beads, 75 μg GALC per experiment) and incubated
with mixing (90 min, 4 °C). Loaded beads were transferred to a ﬂat bottomed 96-
well plate and washed twice in 200 μl pulldown buffer containing 20 mM NaCl,
0.05% Tween-20 or LDAO and appropriate buffer. For the pH screen 100 mM
phosphate buffer encompassing the pH range 4.5–7.5 was used while for sub-
sequent pulldowns 100 mM sodium acetate pH 5.4 was used to more closely match
that used in crystallisation experiments. Concentrated SapA was pre-incubated
with 0.1% Tween-20 or LDAO for 1 hour and 160 µg of SapA was added to GALC-
loaded beads in 200 μl pulldown buffer and incubated with shaking (2 hr, 4 °C).
Beads were then washed for 60 s four times with 200 μl pulldown buffer. Proteins
were eluted with 40 μl 500 mM imidazole, PBS pH 7.4, 0.05% Tween-20 and
analysed by 4–12% gradient Bis-Tris PAGE. Following staining with Coomassie,
gels were scanned on an Odyssey imaging system and band intensity determined
using Image Studio Lite (LI-COR Biosciences). Uncropped gel images from pull-
down experiments are provided in Supplementary Fig. 11.
Protein complex crystallisation. Puriﬁed mSapA was pre-incubated with LDAO
in a ﬁnal mix of 180 µM mSapA with 50 mM sodium acetate pH 5.0, 700 mM NaCl
and 0.1% LDAO. mGALC was concentrated to 90 µM in PBS. Equal volumes of the
mSapA–LDAO complex and puriﬁed mGALC were combined to give a ﬁnal SapA:
GALC molar ratio of 2:1 and incubated at room temperature for 15 min. This
complex was then diluted 1:2 with water for crystallisation trials. Crystallisation
experiments were performed in 48-well sitting drops (800 nL of complex as pre-
pared above plus 800 nL of precipitant) equilibrated at 20 °C against 200 μL
reservoirs of precipitant. Diffraction quality crystals grew against a reservoir of 75
mM sodium citrate pH 5.6 and 11% (w/v) PEG 3350. Crystals were cryoprotected
in reservoir solution supplemented with 20% (v/v) glycerol and ﬂash-cooled by
plunging into liquid nitrogen.
X-ray data collection and structure determination. Diffraction data were
recorded at Diamond Light Source beamline I04-1 on a Pilatus 6 M detector
(Dectris). Diffraction data were collected at 100 K. Data collection statistics are
provided in Table 1. Diffraction data were indexed and integrated using DIALS and
scaled and merged using AIMLESS the xia2 automated data processing pipeline44.
Resolution cut-off was decided by CC1/2 value of> 0.5 and I/σI of 1.5 in the outer
resolution shell45,46. The structure was solved by molecular replacement using
Phaser with mouse GALC (PDB ID 4CCE28) as a search model. Placement of a
model of mouse SapA, based on the structure of the human SapA in a lipoprotein
disc (PDB ID 4DDJ47), and further manual model building was performed using
COOT48. The structure was reﬁned using autobuster49, over-ﬁtting of the data
being minimised by the use of local structure similarity restraints50 to the high-
resolution structure of mouse GALC (PDB ID 4CCE28) and between the NCS-
related GALC and SapA monomers. Model geometry was evaluated with Mol-
Probity throughout the reﬁnement process51. Final reﬁnement statistics are pre-
sented in Table 1. Structural ﬁgures were rendered using PyMOL (Schrödinger
LLC).
Structure analysis. The analysis of buried surface area and interface interactions
in the GALC–SapA structure was carried out using the ePISA service at the Eur-
opean Bioinformatics Institute, EBI35. Hydrogen bonding representations were
created using LIGPLOT + implementing DIMPLOT to generate schematic dia-
grams of protein–protein interactions52. Structure-based alignments were carried
out using SSM superposition implemented within COOT53. Multiple sequence
alignments were carried out using the MUSCLE service at the EBI54. The ﬁgure of
saposin sequence alignment and conservation was produced using ALINE55. For
the electrostatic potential calculations partial charges were assigned using
PDB2PQR56, which uses PROPKA57 to determine protein pKa values. Electrostatic
surfaces were calculated using APBS58.
Data availability. The atomic coordinates and structure factors for the
GALC–SapA complex have been deposited in the Protein Data Bank under
accession code 5NXB. Other data are available from the corresponding author
upon reasonable request.
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